The SENSCIS trial: nintedanib slows declines in FVC in patients with interstitial lung disease caused by systemic sclerosis
1. The SENSCIS trial, a randomized control trial studying the efficacy of nintedanib, an intracellular tyrosine kinase inhibitor, versus placebo ...